临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 42794-76-3

Midodrine

中文名称:米多君
CAS号:42794-76-3
分子式: C12H18N2O4 分子量: 254.28
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Heart Failure With Reduced Ejection Fraction; Hypotension; LV Dysfunction
研究机构: Ottawa Heart Institute Research Corporation
研发日期: August 1 2024
研发阶段: Phase 2 : Phase 3
Midodrine belongs to the class of medications known as vasopressors. It is an adrenergic alpha-1 agonist.

CAS: 427-51-0

Cyproterone Acetate

中文名称:醋酸环丙孕酮
CAS号:427-51-0
分子式: C24H29ClO4 分子量: 416.94
产品形式: free base
研发状态: Completed
研发用途: Signs of Androgenisation in Women e.g. Hirsutism Androgenetic Alopecia Acne and Seborrhea; Hypersexuality in Men; Sexual Deviations in Men; Prostate Cancer
研究机构: Bayer
研发日期: October 18 2021
研发阶段: --
Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity.

CAS: 426219-18-3

Orteronel

中文名称:6-(6,7-二氢-7-羟基-5H-吡咯并[1,2-c]咪唑-7-基)-n-甲基-2-萘羧酰胺
CAS号:426219-18-3
分子式: C18H17N3O2 分子量: 307.35
产品形式: free base
研发状态: Completed
研发用途: Post Menopausal Hormone Receptor Positive Breast Cancer
研究机构: University of Wisconsin Madison; Millennium Pharmaceuticals Inc.
研发日期: Nov-12
研发阶段: Phase 1
Orteronel(TAK-700) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). TAK-700 (Orteronel) is an androgen biosynthesis inhibitor. Phase 3.

CAS: 425637-18-9

Sotrastaurin (AEB071)

中文名称:3-(1H-吲哚-3-基)-4-[2-(4-甲基哌嗪-1-基)喹唑啉-4-基]吡咯-2,5-二酮
CAS号:425637-18-9
分子式: C25H22N6O2 分子量: 438.48
产品形式: free base
研发状态: Completed
研发用途: Uveal Melanoma
研究机构: Columbia University
研发日期: November 19 2014
研发阶段: Phase 1
Sotrastaurin (AEB071) is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.

CAS: 425386-60-3

Semagacestat (LY450139)

中文名称:司马西特
CAS号:425386-60-3
分子式: C19H27N3O4 分子量: 361.44
产品形式: free base
研发状态: Completed
研发用途: Alzheimer''s Disease
研究机构: Eli Lilly and Company
研发日期: Dec-09
研发阶段: Phase 3
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.

CAS: 423-55-2

Perflubron

中文名称:全氟溴辛烷
CAS号:423-55-2
分子式: C8BrF17 分子量: 498.96
产品形式: Free Base
研发状态: Completed
研发用途: Bronchopulmonary Dysplasia
研究机构: Children''s Hospital of Philadelphia; Auto Dealers Caring for Kids Foundation
研发日期: June 27 2017
研发阶段: Phase 1
Perflubron (1-Bromoperfluorooctane, Perfluorooctyl bromide, Oxygent, PFOB) exhibits anti-inflammatory activity thus decreases cytokine production in human alveolar macrophages. Perflubron also attenuates oxidative damage to both biological and nonbiological systems which is independent of its anti-inflammatory properties.